Navigation Links
Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
Date:7/13/2009

ALLEGAN, Mich., July 13 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex lozenge USP, 2 mg and 4 mg in cherry and cinnamon flavors.

The new products will be marketed under store brand labels and are comparable to GlaxoSmithKline's Commit(R) lozenge, which is an aid to smoking cessation. Perrigo's Chairman and CEO Joseph C. Papa stated, "These two approvals expand our exclusive position in the store brand nicotine lozenge category. The expanded range of smoking cessation products also includes coated mint and Fruit Chill(TM) flavored gum, uncoated gum and lozenges." The smoking cessation category is selling at an annual rate estimated at approximately $1 billion at all retail outlets. We expect to begin shipments in the near future.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
2. Perrigo Reports Record Third Quarter
3. Perrigo Company Announces Quarterly Dividend
4. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
5. Perrigo Begins Shipments of Ibuprofen PM
6. Perrigo Reports Record Second Quarter Sales
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
9. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
10. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
11. Perrigo Announces FDA Final Approval for Ibuprofen PM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan Insurance Agency debuts the ... of Michigan. The new initiative fundraises for the Kalamazoo Humane Society (KHS), which ... animal protection and welfare by addressing the root causes of pet overpopulation. As ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon Dr. James Veltmeyer, ... announced his candidacy for the 52nd Congressional District currently held by Representative Scott Peters. ... to this country at age eleven after suffering homelessness and hardship in a distant ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA ... Management System has assisted multiple clients in successfully passing audits such as ... Control Level 2 (AICPA SOC Level 2), and State Data Use Agreement Audits. ...
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... Western University ... health and education to launch the University’s new Center for Innovation on Wednesday, September ... Health Education Center Lecture Hall 1, followed by a technology exhibition from 1 to ...
(Date:8/19/2017)... ... August 19, 2017 , ... Curl Keeper® is excited ... The Curl Leaders, Editors’ Choice 2017 Award for the second year in a row. ... stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies and Best ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
Breaking Medicine Technology: